We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 10, 2020

Alpelisib Plus Fulvestrant for PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1
Ann. Oncol 2020 Nov 24;[EPub Ahead of Print], F André, EM Ciruelos, D Juric, S Loibl, M Campone, IA Mayer, G Rubovszky, T Yamashita, B Kaufman, YS Lu, K Inoue, Z Pápai, M Takahashi, F Ghaznawi, D Mills, M Kaper, M Miller, PF Conte, H Iwata, HS Rugo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading